Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort results

David R. Spigel, Shaker R. Dakhil, J. Thaddeus Beck, A. Sadiq, Sreedevi K. Menon, Charles Webb, Frank Tsai, Melissa L. Johnson, Suzanne F. Jones, Carol Greenlees, Dawn Michelle Stults, Donald K. Strickland, Carl Cook, Ganesh Mugundu, Naomi Laing, Tim French, Howard A. BurrisAnnals 2016 · DOI

BibTeX
@article{spigel2016phase,
  author = {David R. Spigel and Shaker R. Dakhil and J. Thaddeus Beck and A. Sadiq and Sreedevi K. Menon and Charles Webb and Frank Tsai and Melissa L. Johnson and Suzanne F. Jones and Carol Greenlees and Dawn Michelle Stults and Donald K. Strickland and Carl Cook and Ganesh Mugundu and Naomi Laing and Tim French and Howard A. Burris},
  title = {{Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort results}},
  journal = {Annals},
  year = {2016},
  doi = {10.1093/annonc/mdw368.22},
}

Loading related content...

Figure